Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database
  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

Cont fu of Evolt R and PRO Sys Low Risk cohort PAS


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Ongoing
Application Number /
Requirement Number		 P130021 S058/ PAS001
Date Original Protocol Accepted 08/16/2019
Date Current Protocol Accepted 12/23/2023
Study Name Cont fu of Evolt R and PRO Sys Low Risk cohort PAS
Device Name Medtronic CoreValve™ Evolut™ R System and Medtronic CoreValve™ Evolut™ Pro System
Clinical Trial Number(s) NCT02701283  
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Concurrent Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives Continued follow-up of all living subjects who were enrolled in the pivotal cohort under the IDE. The objective of this study is to characterize the clinical outcomes annually through 10 years post-procedure.
Study Population All living subjects who were enrolled in the IDE pivotal cohort.
Sample Size All living subjects.
Key Study Endpoints All-cause mortality, all stroke (disabling and non-disabling), life-threatening bleeding, acute kidney injury at stage 2 or 3, coronary artery obstruction requiring intervention, major vascular complication, valve-related dysfunction requiring repeat procedure, new permanent pacemaker implantation, prosthetic valve endocarditis, prosthetic valve thrombosis, New York Heart Association (NYHA) classification, Kansas City Cardiomyopathy Questionnaire (KCCQ) score, and hemodynamic performance metrics by Doppler echocardiography.
Follow-up Visits and Length of Follow-up 10 years
Interim or Final Data Summary
Interim Results At 36 months:
All-cause mortality: 6.3% (TAVR); 8.2% (SAVR)
All stroke (disabling and non-disabling): 7.4% (TAVR); 6.6% (SAVR)
Life-threatening bleeding: 4.7% (TAVR); 10.3% (SAVR)
AKI Stage 3: 0.4% (TAVR); 1.9% (SAVR)
Coronary Obstruction: 0.8% (TAVR); 0.3% (SAVR)
Major Vascular Complications: 4.1% (TAVR); 3.7% (SAVR)
Reintervention: 1.0% (TAVR); 1.1% (SAVR)
New permanent pacemaker implantation: 23.2% (TAVR); 9.1% (SAVR)
Prosthetic valve endocarditis: 0.7% (TAVR); 1.4% (SAVR)
Prosthetic valve thrombosis: 0.3% (TAVR); 0.2% (SAVR)
NYHA (% in class I/II): 91.2% (TAVR); 88.1% (SAVR)
KCCQ (Mean Change from Baseline): 20.1 (TAVR); 19.3 (SAVR)
Transvalvular mean gradient: 9.09 (TAVR); 12.12 (SAVR)
Effective orifice area: 2.20 (TAVR); 1.97 (SAVR)
Greater than or equal to Moderate Total Aortic Regurgitation: 0.9% (TAVR); 0.4% (SAVR)
Actual Number of Patients Enrolled 1478 enrolled; 737 TAVR and 741 SAVR
Actual Number of Sites Enrolled 87
Patient Follow-up Rate At 36 months (patient status known):
TAVR: 92%
SAVR: 86%


Cont fu of Evolt R and PRO Sys Low Risk cohort PAS Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
1 year report 03/31/2020 03/31/2020 On Time
2 year report 03/31/2021 03/30/2021 On Time
3 year report 09/30/2022 09/27/2022 On Time
4 year report 09/30/2023 09/27/2023 On Time
5 year report 09/30/2024    
6 year report 09/30/2025    
7 year report 09/30/2026    
8 year report 09/30/2027    
9 year report 09/30/2028    
10 year report 09/30/2029    


Contact Us
Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-